Showing 133–144 of 192 resultsSorted by latest
Pharma & Biotech
In the second quarter, JNJ made significant progress across various areas.
Pfizer’s revenue is benefiting significantly from Seagen products.
In January 2023, Baxter planned to spin off its Kidney Care business into a separate company.
Repatha experienced a 46% year-over-year increase in volume, although lower net selling prices partially offset this.
Twist Bioscience is a synthetic biology and genomics company that created a scalable DNA synthesis platform to advance biological engineering.
BDX’s 2025 growth strategy focuses on growing, simplifying, and empowering.
In Europe, Medtronic began a limited launch of the Simplera Sync with 780G, with a full launch planned for summer. Early feedback is very positive. Simplera Sync is smaller, disposable, and easier to use. Medtronic has also submitted it for FDA approval in the US.
REDY launched 181 products across geographies in FY2024. In Q1FY25, they launched 3 new products in the U.S., 12 new products across various countries in the Europe region and 13 new brands in India, in addition to exclusive rights to promote and distribute Sanofi’s vaccine brands.
For the company, there has been increased demand for its services, such as moving and setting up laboratories quickly.
LLY submitted mirikizumab for approval in the U.S. and EU to treat severe Crohn’s disease, and resubmitted lebrikizumab for severe atopic dermatitis in the U.S. LLY received EU approval for the multi-dose KwikPen for Mounjaro and plans to launch it soon.
SYK reports strong performance from the Mako direct-to-patient campaign, driving significant growth with record first-quarter installations in the U.S. and internationally.
GILD acquired CymaBay Therapeutics, gaining access to seladelpar, a potential treatment for liver disease.